Organization
Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ
2 abstracts
Abstract
International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).Org: Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Los Angeles, CA, Seoul National University Hospital, Seoul, South Korea,
Abstract
Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study.Org: Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, Division of Urology, IREC, Cliniques Universitaires Saint Luc, UCLouvain, Brussels, Belgium, Northwestern University, Feinberg School of Medicine, Chicago, IL, Bayer Healthcare Company Ltd., Beijing, China, Bayer Healthcare Co Ltd, Beijing, China,